It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Due to commonalities in pathophysiology, age-related macular degeneration (AMD) represents a uniquely accessible model to investigate therapies for neurodegenerative diseases, leading us to examine whether pathways of disease progression are shared across neurodegenerative conditions. Here we use single-nucleus RNA sequencing to profile lesions from 11 postmortem human retinas with age-related macular degeneration and 6 control retinas with no history of retinal disease. We create a machine-learning pipeline based on recent advances in data geometry and topology and identify activated glial populations enriched in the early phase of disease. Examining single-cell data from Alzheimer’s disease and progressive multiple sclerosis with our pipeline, we find a similar glial activation profile enriched in the early phase of these neurodegenerative diseases. In late-stage age-related macular degeneration, we identify a microglia-to-astrocyte signaling axis mediated by interleukin-1β which drives angiogenesis characteristic of disease pathogenesis. We validated this mechanism using in vitro and in vivo assays in mouse, identifying a possible new therapeutic target for AMD and possibly other neurodegenerative conditions. Thus, due to shared glial states, the retina provides a potential system for investigating therapeutic approaches in neurodegenerative diseases.
Single-nucleus RNA-seq was used to profile 11 retinas with varying stages of age-related macular degeneration and 6 control retinas. The authors identified shared glial states across neurodegeneration, indicating that the retina provides a human system for investigating therapeutic approaches in neurodegeneration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Yale University, Department of Neuroscience, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
2 Yale University, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
3 Yale University, Department of Ophthalmology and Visual Science, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
4 Yale University, Department of Neuroscience, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Department of Neurology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
5 Yale School of Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
6 University of Manchester, Division of Infection, Immunity and Respiratory Medicine, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
7 Yale University, Department of Computer Science, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
8 Yale University, Department of Applied Math, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
9 Yale University, Computational Biology, Bioinformatics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
10 Yale University School of Medicine, Department of Immunobiology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
11 Mila—Quebec AI institute, Montréal, Canada (GRID:grid.510486.e); Université de Montréal, Department of Mathematics and Statistics, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
12 Rutgers University, Department of Computer Science, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
13 Yale University, Department of Genetics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
14 Michigan State University, Department of Computational Mathematics, Science and Engineering, East Lansing, USA (GRID:grid.17088.36) (ISNI:0000 0001 2150 1785); Michigan State University, Department of Mathematics, East Lansing, USA (GRID:grid.17088.36) (ISNI:0000 0001 2150 1785)
15 ETH Zurich, Department of Biosystems Science and Engineering, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
16 Yale University, Department of Computer Science, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Department of Genetics, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
17 Yale University, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University, Department of Ophthalmology and Visual Science, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)